Yondelis
Yondelis ingredients
| Active ingredient | Strength |
|---|---|
| Trabectedin | .05 mg/mL |
What Yondelis is used for
The FDA lists the approved uses on the official label (below). In the EU, trabectedin is approved as Yondelis for:
Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Yondelis
- Generic name
- Trabectedin
- Made by
- Janssen Products, LP
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Alkylating Drug
- FDA approval
- New drug application (NDA) NDA207953
- On the US market since
- 2015
Official information
- Yondelis prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Trabectedin)
In India
- Trabectedin: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yondelis?
Yondelis (Trabectedin) is a cancer medicine made by Janssen Products, LP, approved by the US FDA.
What are the ingredients of Yondelis?
Yondelis contains Trabectedin (.05 mg/mL).
Is Yondelis approved in Europe?
The same active substance is approved in the EU as Yondelis.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA